• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Waste Management

Waste Management

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: WM Company delays changes to FX benchmark methodology

    UPDATE: WM Company delays changes to FX benchmark methodology

  2. Aldi, Lidl Post Record Market Shares - Kantar

    Aldi, Lidl Post Record Market Shares - Kantar

  3. LONDON MARKETS: Tesco Hits 14-year Low In London After Warning

    LONDON MARKETS: Tesco Hits 14-year Low In London After Warning

  4. IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

  5. Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

  6. IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

  7. Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

    Longer Follow-Up IMBRUVICA® (ibrutinib) Treatment Demonstrates Sustained Efficacy in Patients with Difficult-to-Treat Chronic Lymphocytic Leukemia (CLL)

  8. IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

    IMBRUVICA® (ibrutinib) in Combination with Rituximab Data Shows Positive Benefit-Risk Profile in Hematologic Malignancy

  9. IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

    IMBRUVICA® (ibrutinib) Data Demonstrates Safety and Durability of Response at Two-Year Follow-up in Mantle Cell Lymphoma

  10. IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

    IMBRUVICA® (ibrutinib) Data Suggests Promise in Multiple Myeloma

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.